(0.32%) 5 116.43 points
(0.30%) 38 356 points
(0.37%) 15 987 points
(-0.95%) $83.05
(5.36%) $2.03
(0.28%) $2 353.80
(0.42%) $27.65
(4.16%) $960.45
(-0.27%) $0.932
(-0.45%) $10.98
(-0.57%) $0.796
(1.63%) $93.37
Live Chart Being Loaded With Signals
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States...
Stats | |
---|---|
本日の出来高 | 7 147.00 |
平均出来高 | 41 765.00 |
時価総額 | 674 016 |
EPS | $0 ( 2024-03-29 ) |
次の収益日 | ( $0 ) 2024-06-06 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.0600 |
ATR14 | $0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-10-13 | Puissance Capital Management Lp | Sell | 1 076 841 | Common Stock |
2023-06-07 | Amin Naseem | Buy | 47 578 | Common Stock |
2023-06-07 | Fernandes Peter | Sell | 100 000 | Stock Options (Right to Buy) |
2023-06-07 | Shah Parag Suresh | Sell | 50 000 | Stock Options (Right to Buy) |
2023-06-07 | Dekker Martin | Sell | 50 000 | Stock Options (Right to Buy) |
INSIDER POWER |
---|
-74.13 |
Last 99 transactions |
Buy: 6 532 145 | Sell: 5 633 542 |
Bellerophon Therapeutics 相関
10 最も負の相関 | |
---|---|
CMLS | -0.959 |
JRJC | -0.949 |
AADI | -0.947 |
CPTN | -0.944 |
MICS | -0.942 |
IHRT | -0.942 |
MDRX | -0.942 |
EYE | -0.941 |
ESSA | -0.94 |
SILK | -0.938 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Bellerophon Therapeutics 財務諸表
Annual | 2022 |
収益: | $0 |
総利益: | $0 (0.00 %) |
EPS: | $-2.08 |
FY | 2022 |
収益: | $0 |
総利益: | $0 (0.00 %) |
EPS: | $-2.08 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-1.870 |
FY | 2020 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-3.17 |
Financial Reports:
No articles found.
Bellerophon Therapeutics
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。